Peptide drug development has progressed through distinct generational phases, each characterized by innovations in stability, delivery, and molecular design that overcame the limitations of preceding generations.
Generation Era Key Innovation Examples First 1920s–1970s Native peptides, extraction Insulin, vasopressin, oxytocin Second 1970s–1990s Synthetic analogs, modifications Desmopressin, leuprolide Third 1990s–2010s Long-acting formulations, PEGylation Liraglutide, PEG-growth hormones Fourth 2010s–present Oral peptides, antibody fusions, stapled Semaglutide oral, dulaglutide Fifth 2020s–future Non-peptide mimetics, cell-penetrating Orforglipron, ATGs
Extracted from animal tissues (porcine, bovine)
Short half-lives (minutes)
Parenteral administration only
Limited purity and standardization
Peptide Source Year Application Insulin Porcine/bovine pancreas 1921 Diabetes Oxytocin Posterior pituitary 1906 Labor induction Vasopressin Posterior pituitary 1928 Diabetes insipidus Glucagon Pancreas 1953 Hypoglycemia ACTH Pituitary 1933 Anti-inflammatory
Animal-derived immunogenicity
Batch-to-batch variability
Rapid degradation (t½ = 2–20 min)
Injection required
Limited supply
Solid-phase peptide synthesis (SPPS) enabled reproducible manufacturingAmino acid substitution improved metabolic stabilityD-amino acid incorporation blocked protease recognitionCyclization enhanced conformational stabilityAmidation protected C-terminus from carboxypeptidases
Modification Mechanism Example Benefit D-amino acid Blocks aminopeptidases Desmopressin 4× longer t½ Deamidation Removes Asn deamidation site Desmopressin Chemical stability Cyclization Conformational restriction Octreotide Receptor selectivity Amidation Protects C-terminus Leuprolide Enzymatic stability Substitution Enhances potency Goserelin 10× potency
Peptide Modification Year Application Desmopressin D-Arg8, deamino 1972 Diabetes insipidus Leuprolide D-Leu6, Pro9-NH2 1985 Prostate cancer Goserelin D-Ser6, AzGly10 1986 Prostate cancer Octreotide D-Phe, Cys, cyclization 1988 Acromegaly Nafarelin D-2-Nal6 1990 Endometriosis
Albumin binding (fatty acid acylation)PEGylation (polyethylene glycol conjugation)Microsphere depot formulations (PLGA)** depot implants** (non-biodegradable)
Fc-fusion proteins
Technology Mechanism Half-life Extension Example Fatty acid acylation Albumin binding 10–50× Liraglutide, Insulin detemir PEGylation Renal filtration reduction 5–20× PEG-asparaginase PLGA microspheres Sustained release Months Leuprolide depot Implant rods Zero-order release Months–years Etonogestrel Fc-fusion FcRn recycling 10–20× Etanercept, Dulaglutide Albumin fusion FcRn recycling 10–20× Albugon (albumin-GLP-1)
Peptide Technology Year Half-life Liraglutide C-16 fatty acid (albumin) 2000 13 hrs Insulin detemir C-14 fatty acid (albumin) 2004 5–7 hrs Exenatide ER PLGA microspheres 2012 1 week Dulaglutide Fc-fusion 2014 5 days Semaglutide C-18 fatty acid (albumin) 2012 165 hrs
Oral peptide delivery (absorption enhancers, permeation promoters)Antibody-drug conjugates (peptide-antibody fusions)Stapled peptides (hydrocarbon-stabilized α-helices)Cell-penetrating peptides (intracellular delivery)Multifunctional peptides (dual/multi-receptor agonism)
Technology Mechanism Example Bioavailability SNAC enhancer Transcellular absorption Oral semaglutide ~1% Permeation enhancers Tight junction opening Various (research) 1–10% Non-peptide mimetic Small molecule oral Orforglipron ~50% Enteric coating Gastric protection Various Variable
Peptide Receptors Year Innovation Tirzepatide GLP-1R + GIPR 2022 Dual agonist Retatrutide GLP-1R + GIPR + GCGR 2023 Triple agonist Survodutide GLP-1R + GCGR 2023 Dual agonist
Peptide Technology Year Application Semaglutide oral SNAC enhancer 2019 T2D, Obesity Tirzepatide Dual agonism 2022 T2D, Obesity Orforglipron Non-peptide oral 2023 Obesity Danuglipron Non-peptide oral 2023 Obesity
Technology Mechanism Status RNA-peptide conjugates Targeted delivery + sequence silencing Phase I/II Peptide-drug conjugates Cytotoxic payload delivery Phase II/III Circular peptides Protease-resistant macrocycles Preclinical Peptide nucleic acids Antisense-like binding Preclinical Cell-penetrating peptides Intracellular cargo delivery Phase I Engineered peptide macrocycles Phage display-selected Phase I/II
Oral bioavailability >10% without enhancersHalf-life >1 week through non-albumin mechanismsIntracellular targets accessible via cell-penetrating sequencesMulti-specificity targeting 3+ receptors simultaneouslyComputational design with AI-driven sequence optimization
1920s ──── 1950s ──── 1970s ──── 1990s ──── 2010s ──── 2020s
Native Recombinant SPPS Long-acting Oral AI-designed
extraction proteins synthetic formulations peptides peptides
Insulin Human Desmo- Liraglutide Oral Orforglipron
(porcine) insulin pressin Dulaglutide sema Retatrutide
Generation Market Share (2024) Revenue Key Driver First <5% Declining Legacy products Second 10–15% Stable Generic availability Third 40–50% Growing GLP-1 agonist dominance Fourth 30–35% Rapidly growing Oral peptides, dual agonists Fifth <5% Emerging Pipeline products
Each generation of peptide drugs has addressed specific limitations of its predecessors:
First → Second : Synthetic control eliminated animal-derived variabilitySecond → Third : Long-acting technologies reduced dosing frequency from multiple daily to once weekly/monthlyThird → Fourth : Oral delivery and multifunctional peptides improved convenience and efficacyFourth → Fifth : AI design and novel modalities will enable intracellular targets and ultra-long-acting formulations
The trajectory is toward peptides that are orally bioavailable, ultra-long-acting, multi-specific, and computationally optimized — approaching the convenience of small molecules while retaining the potency and selectivity of biologics.
